MERIBANK BIOTECH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.15 TWD | +0.13% |
|
+0.66% | +0.13% |
| 21/03 | Meribank Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Meribank Biotech Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 18Cr 55.34L 46Cr | Sales 2023 | 23Cr 72L 60Cr | Capitalization | 239.18Cr 7.35Cr 612.95Cr |
|---|---|---|---|---|---|
| Net income 2022 | -10Cr -31.34L -26Cr | Net income 2023 | -12Cr -38.41L -32Cr | EV / Sales 2022 * | - |
| Net cash position 2022 | 16Cr 49.78L 42Cr | Net cash position 2023 | 37Cr 1.12Cr 94Cr | EV / Sales 2023 | 8.65 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-19.1
x | Employees | 142 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.82% |
More Fundamentals
* Assessed data
| 1 day | +0.13% | ||
| 1 week | +0.66% | ||
| Current month | +0.13% | ||
| 3 months | +1.73% | ||
| 6 months | +0.13% | ||
| Current year | +0.13% |
1 week
36.55
38.65
1 month
36.3539.10
Current year
31.5541.50
1 year
31.5550.70
3 years
27.8553.50
5 years
27.8553.50
10 years
27.8553.50
| Managers | Title | Age | Since |
|---|---|---|---|
Shi Yang Wu
CEO | Chief Executive Officer | - | - |
Qi Ming Pan
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang You Xuan
CHM | Chairman | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 38.15 | +0.13% | 679 182 |
| 28/24/28 | 38.1 | +0.40% | 190,584 |
| 27/24/27 | 37.95 | +1.07% | 256,184 |
| 26/24/26 | 37.55 | -0.27% | 447,216 |
| 25/24/25 | 37.65 | -1.57% | 211,886 |
End-of-day quote Taipei Exchange, July 01, 2024
More quotes
Meribank Biotech Co Ltd is a Taiwan-based company mainly engaged in the stem cell storage business. The Company is engaged in the provision of cord blood (hematopoietic stem cells) storage and application services, placenta and umbilical cord (mesenchymal stem cells) storage and application services, peripheral blood stem cell storage service and application service, and promotion of stem cell transplantation application, development of new stem cell processing technology and storage application services. The Company also develops allogeneic umbilical cord mesenchymal stem cell manufacturing and therapeutic applications.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.13% | 8.32Cr | |
| +17.09% | 8.41TCr | |
| -25.72% | 7.41TCr | |
| -0.35% | 2.68TCr | |
| -10.81% | 1.72TCr | |
| +0.82% | 1.68TCr | |
| -0.69% | 1.52TCr | |
| +72.06% | 1.33TCr | |
| +76.53% | 1.3TCr | |
| -25.61% | 1.28TCr |
- Stock Market
- Equities
- 4724 Stock
